Danaher Corporation $DHR Shares Acquired by Townsend Asset Management Corp NC ADV

Townsend Asset Management Corp NC ADV boosted its position in Danaher Corporation (NYSE:DHR) by 13.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,237 shares of the conglomerate’s stock after purchasing an additional 3,618 shares during the period. Danaher comprises 2.2% of Townsend Asset Management Corp NC ADV’s investment portfolio, making the stock its 12th biggest position. Townsend Asset Management Corp NC ADV’s holdings in Danaher were worth $6,193,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Ceredex Value Advisors LLC boosted its stake in shares of Danaher by 1.6% during the 2nd quarter. Ceredex Value Advisors LLC now owns 249,377 shares of the conglomerate’s stock worth $49,262,000 after purchasing an additional 3,862 shares during the last quarter. Chicago Capital LLC raised its position in shares of Danaher by 11.6% in the second quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock valued at $2,634,000 after buying an additional 1,391 shares during the last quarter. Weitz Investment Management Inc. lifted its stake in shares of Danaher by 6.1% during the second quarter. Weitz Investment Management Inc. now owns 526,950 shares of the conglomerate’s stock valued at $104,094,000 after buying an additional 30,300 shares during the period. UniSuper Management Pty Ltd boosted its position in Danaher by 1.6% during the first quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate’s stock worth $34,954,000 after acquiring an additional 2,667 shares during the last quarter. Finally, Nvwm LLC grew its stake in Danaher by 20.4% in the 2nd quarter. Nvwm LLC now owns 7,093 shares of the conglomerate’s stock worth $1,401,000 after acquiring an additional 1,204 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Performance

Danaher stock opened at $230.52 on Friday. The company has a market cap of $162.83 billion, a price-to-earnings ratio of 47.53, a price-to-earnings-growth ratio of 4.48 and a beta of 0.89. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $258.23. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. The stock’s 50-day moving average is $222.66 and its 200-day moving average is $208.15.

Danaher (NYSE:DHR) last posted its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. The firm had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company’s revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.71 EPS. Equities analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be issued a dividend of $0.32 per share. The ex-dividend date is Friday, December 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s payout ratio is presently 26.39%.

Insider Buying and Selling

In related news, SVP Georgeann Couchara sold 5,174 shares of the stock in a transaction on Monday, November 10th. The stock was sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the sale, the senior vice president directly owned 2,625 shares in the company, valued at approximately $552,352.50. This represents a 66.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the transaction, the senior vice president owned 14,553 shares in the company, valued at approximately $3,190,454.19. This represents a 59.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 30,248 shares of company stock valued at $6,609,663. Company insiders own 11.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on DHR shares. Morgan Stanley started coverage on Danaher in a research note on Monday, December 1st. They set an “overweight” rating and a $270.00 price target on the stock. TD Cowen increased their target price on Danaher from $250.00 to $260.00 and gave the stock a “buy” rating in a research report on Wednesday, October 22nd. Robert W. Baird set a $247.00 price target on Danaher in a research note on Wednesday, October 22nd. Wells Fargo & Company lifted their price target on Danaher from $230.00 to $240.00 and gave the company an “equal weight” rating in a report on Monday, December 15th. Finally, HSBC increased their price objective on shares of Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a report on Monday, December 1st. Twenty-one investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $248.25.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.